Westchester Avenue

Northpath Investments Secures $17.5M in Refinancing for Westchester County Office Assets in White Plains, New York

Retrieved on: 
Thursday, August 3, 2023
Life, Westchester County Airport, Westchester Avenue, Tenant, Capital market, Senior management, Commercial property, Wegmans

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Northpath Investments (“Northpath”), a privately held real estate investment firm headquartered in New York City, is excited to announce the refinancing of 2 and 4 Westchester Park Drive with a $17.5 million loan from Centerville Bank.

Key Points: 
  • NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Northpath Investments (“Northpath”), a privately held real estate investment firm headquartered in New York City, is excited to announce the refinancing of 2 and 4 Westchester Park Drive with a $17.5 million loan from Centerville Bank.
  • Enjoying an occupancy rate of 86.5%, 2 and 4 Westchester Park Drive are home to a diverse tenant mix of traditional office and medical office/healthcare users.
  • JLL’s Capital Markets arranged a permanent, fixed-rate loan to refinance 2-4 Westchester Park Drive, two adjoining 5-story office/medical buildings.
  • We are excited to continue driving growth and creating value in the Westchester County office market.”

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

Retrieved on: 
Thursday, September 8, 2022
Telephone, CEO, Prospectus, Safety, Caladrius Biosciences, Nasdaq, Therapy, CD34, Doctor of Philosophy, Time, Sale, Person, Risk, Investor relations, SEC, Review, List of life sciences, GLOBE, SEC filing, Conference, Company, Kidney disease, Communication, Failure, Internet, Form, THE, Annual report, Clinical trial, Intellectual property, Private Securities Litigation Reform Act, Westchester Avenue, Nature, Pharmaceutical industry, Security (finance), Bank, Caladrius

Life Sciences Investor Forum Virtual Conference (September 15, 2022)

Key Points: 
  • Life Sciences Investor Forum Virtual Conference (September 15, 2022)
    An archived webcast will be available following the conclusion of the event.
  • It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.
  • Information about Caladrius directors and executive officers is included in Caladrius Annual Report on Form10-K for the year ended December31, 2021, filed with the SEC on March22, 2022 and amended on April 21, 2022.

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Retrieved on: 
Wednesday, August 10, 2022
Telephone, CD34, Risk, GLOBE, Death, Neoplasm, Form, Failure, Drug resistance, SEC, Cancer, Integrin, Clinical trial, Annual report, Communication, Patient, Pancreatic cancer, Tumor microenvironment, CendR, Collection, Immunosuppression, Investor relations, Kidney disease, Technology, Private Securities Litigation Reform Act, Sale, Nasdaq, Neuropilin, SAN, Safety, Nature, Immunotherapy, THE, Person, Intellectual property, Drug Master File, Caladrius Biosciences, Prospectus, Roche, Therapy, Westchester Avenue, Time, Internet, Review, Company, PDAC, Pharmaceutical industry, Medical imaging, Security (finance), Caladrius

BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”) and Cend Therapeutics, Inc. (“Cend”), today announced Cend’s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate Cend’s lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq®), Roche’s PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (“mPDAC”). Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study.

Key Points: 
  • We are truly delighted to report progress regarding the development of CEND-1 supported by our collaboration agreement with Cend.
  • Caladrius commitment of resources, including its investment in Cend, provide support for this collaboration.
  • We are excited to work with Roche as Caladrius and Cend combine to form Lisata Therapeutics, stated David Mazzo, Ph.D., Chief Executive Officer of Caladrius.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Telephone, CD34, Risk, Board of directors, GLOBE, Form, Failure, SEC, Catheter, Investment, Clinical trial, CMD, Annual report, Communication, Patient, Microcirculation, Pharmaceuticals and Medical Devices Agency, Medicines and Healthcare products Regulatory Agency, CendR, CLI, Medication, Investor relations, Kidney disease, FREEDOM, Diagnosis, Private Securities Litigation Reform Act, Sale, Conference call, The Lancet, Nasdaq, Safety, Nature, Conference, THE, University, Person, Intellectual property, Trial master file, Caladrius Biosciences, DKD, Prospectus, Therapy, Cell, COVID-19, Program, Westchester Avenue, Kidney, Investor, PMDA, Time, Internet, FDA, Review, Data monitoring committee, Company, Board, Research, EDT, Pharmaceutical industry, Internet service provider, Bank, Security (finance), Caladrius

BASKING RIDGE, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update.

Key Points: 
  • The second quarter of 2022 was a transformative and energizing quarter for Caladrius with the announcement of our proposed merger with Cend Therapeutics (Cend).
  • The Company treated the first patient in April 2022 and completed treatment for all six subjects during the third quarter of 2022.
  • Caladrius will hold a live conference call today, August 4, 2022, at 4:30 p.m. (EDT) to discuss financial results, provide a business update and answer questions.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

Retrieved on: 
Wednesday, July 6, 2022
Patient, CendR, Saint John, Immunosuppression, GLOBE, Cancer, Progression-free survival, Company, Kidney disease, Communication, Integrin, Investor relations, Nature, Therapy, European Society for Medical Oncology, Nasdaq, Intellectual property, Prospectus, Telephone, Pancreatic cancer, Pharmacokinetics, SAN, ESMO, Person, THE, CD34, SEC, Risk, Time, Congress, Neuropilin, Survivor, Failure, Technology, Private Securities Litigation Reform Act, Particle-size distribution, Caladrius Biosciences, Cell, Review, Oncology, Annual report, SOC, Internet, Sale, Toxic epidermal necrolysis, Neoplasm, Clinical trial, The Lancet, Medicine, Tumor microenvironment, Safety, St. John of God Hospital, Stillorgan, Hepatology, Westchester Avenue, Pharmaceutical industry, Medical imaging, Security (finance), Caladrius

The protective meshwork, or tumor stroma, that surrounds the cancer cells has proved a difficult barrier for chemotherapy drugs to penetrate.

Key Points: 
  • The protective meshwork, or tumor stroma, that surrounds the cancer cells has proved a difficult barrier for chemotherapy drugs to penetrate.
  • These results reinforce our belief that CEND-1 could become a transformative new medicine for the treatment of pancreatic cancer and other difficult-to-treat solid tumor cancers.
  • The data in the publication expand on the preliminary findings presented at the 2020 European Society for Medical Oncology (ESMO) Congress.
  • The Company recently announced that it has signed a definitive merger agreement with Cend Therapeutics, Inc. ( www.cendrx.com ) to form Lisata Therapeutics.

Coviello Weber & Dahill LLP Launches New Law Firm with Longtime Colleagues

Retrieved on: 
Tuesday, June 7, 2022
Suite, Partnership, Employment, Friends, Topical steroid withdrawal, Coviello, Bankruptcy, Westchester Avenue, Fraud, Private investigator, Insurance

WHITE PLAINS, N.Y., June 7, 2022 /PRNewswire/ -- Coviello Weber & Dahill LLP announced today the formation of a new law firm founded by brothers Gerald and Jeff Coviello, and their longtime colleagues William "Bill" Dahill and Paul Weber.

Key Points: 
  • WHITE PLAINS, N.Y., June 7, 2022 /PRNewswire/ -- Coviello Weber & Dahill LLP announced today the formation of a new law firm founded by brothers Gerald and Jeff Coviello, and their longtime colleagues William "Bill" Dahill and Paul Weber.
  • The firm pairs the transactional and business advisory skills of Gerald Coviello and Paul Weber with the commercial litigation talents of Jeff Coviello and Bill Dahill.
  • "The launch of Coviello Weber & Dahill LLP is the realization of a long-held dream to start a law firm with my brother, where our shared core values of integrity, justice, and the pursuit of excellence will guide our work for our clients," said Managing Partner Gerald Coviello.
  • Coviello Weber & Dahill LLP is headquartered at 707 Westchester Avenue, Suite 300, White Plains, New York 10604.

Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement

Retrieved on: 
Wednesday, April 27, 2022
CD34, Risk, GLOBE, Sale, Patient, PDAC, Review, Event, Technology, Prospectus, Director, European Society for Medical Oncology, Tumor microenvironment, Therapy, THE, Investor, Consultant, Domestic, Westchester Avenue, Investor relations, Annual report, Proxy, Private Securities Litigation Reform Act, RNA, Doctor of Philosophy, Cell, Company, Nasdaq, Board of directors, CendR, Nature, CEO, Board, International, MD, Pancreatic cancer, Intellectual property, Internet, Failure, Communication, SEC, Caladrius Biosciences, Safety, Time, Cancer, Telephone, Clinical trial, Immunotherapy, SAN, Neoplasm, Person, Breast, Immunosuppression, Webcast, ESMO, Phase 1, Kidney disease, Pharmaceutical industry, Medical imaging, Security (finance), Caladrius

Following closing, the combined company will be renamed Lisata Therapeutics, Inc. (Lisata) and will trade on the Nasdaq under the ticker symbol LSTA.

Key Points: 
  • Following closing, the combined company will be renamed Lisata Therapeutics, Inc. (Lisata) and will trade on the Nasdaq under the ticker symbol LSTA.
  • The merger is currently expected to close in the third quarter of 2022 subject to the approval of Caladrius and Cend stockholders as well as the satisfaction of certain other customary closing conditions and applicable approvals.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.
  • In connection with the proposed transaction between Caladrius and Cend, Caladrius intends to file relevant materials with the SEC, including a registration statement that will contain a proxy statement and prospectus.

Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement

Retrieved on: 
Wednesday, April 27, 2022
CD34, Risk, GLOBE, Sale, Patient, PDAC, Review, Event, Technology, Prospectus, Director, European Society for Medical Oncology, Tumor microenvironment, Therapy, THE, Investor, Consultant, Domestic, Westchester Avenue, Investor relations, Annual report, Proxy, Private Securities Litigation Reform Act, RNA, Doctor of Philosophy, Cell, Company, Nasdaq, Board of directors, CendR, Nature, CEO, Board, International, MD, Pancreatic cancer, Intellectual property, Internet, Failure, Communication, SEC, Caladrius Biosciences, Safety, Time, Cancer, Telephone, Clinical trial, Immunotherapy, SAN, Neoplasm, Person, Breast, Immunosuppression, Webcast, ESMO, Phase 1, Kidney disease, Pharmaceutical industry, Medical imaging, Security (finance), Caladrius

Following closing, the combined company will be renamed Lisata Therapeutics, Inc. (Lisata) and will trade on the Nasdaq under the ticker symbol LSTA.

Key Points: 
  • Following closing, the combined company will be renamed Lisata Therapeutics, Inc. (Lisata) and will trade on the Nasdaq under the ticker symbol LSTA.
  • The merger is currently expected to close in the third quarter of 2022 subject to the approval of Caladrius and Cend stockholders as well as the satisfaction of certain other customary closing conditions and applicable approvals.
  • Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease.
  • In connection with the proposed transaction between Caladrius and Cend, Caladrius intends to file relevant materials with the SEC, including a registration statement that will contain a proxy statement and prospectus.

LMP Announces the Closing of its Acquisition of White Plains Chrysler Dodge Jeep Ram Dealership in New York is Expected to be Completed by Wednesday October 6th

Retrieved on: 
Friday, October 1, 2021
Jeep, Securities Act of 1933, Emory University, Solution, Chrysler, NASDAQ, Transport, Region, GLOBE, CEO, Westchester Avenue, Industry, Acquisition, Growth, LMP, Technology, Dodge, MBA, Maintenance, Forward-looking statement, Securities Exchange Act of 1934, SEC, Management, Car dealership, Risk management

The Chrysler Dodge Jeep Ram franchises are located at 70 Westchester Avenue, White Plains, New York 10601.

Key Points: 
  • The Chrysler Dodge Jeep Ram franchises are located at 70 Westchester Avenue, White Plains, New York 10601.
  • Upon the closing of the acquisition, Mr. Grant will be Regional Vice President at LMP, Partner, as well as Dealer Operator of the acquired dealership.
  • Mr. Aldahan concluded, The operating assets to be acquired include four new vehicle franchises consisting of: one Chrysler, one Dodge, one Jeep and one Ram.
  • You are cautioned not to place undue reliance on forward-looking statements, which reflect expectations only as of this date.

PDL Community Bancorp Announces an Agreement of Sale and Leaseback of Real Property

Retrieved on: 
Wednesday, September 1, 2021
Company, Community development, PFS, Private Securities Litigation Reform Act, Government, Federal Housing Administration, Fraud, Lists of disasters, Westchester Avenue, Securities Act of 1933, U.S. Securities and Exchange Commission, GLOBE, Securities Exchange Act of 1934, Small business, Association, Regulation, Small Business Administration, Federal Home Loan Banks, Federal government of the United States, PDL, Uniform Relocation Assistance and Real Property Acquisition Act (1970), Investment, FHA, Risk, Bank, New York State Department of Financial Services, Safety, External commercial borrowing, CEO, Financial services, Sale, Community development financial institution, Real property, COVID-19, Mission statement, Annual report, Security (finance)

The sale price of the Real Property is $16.1 million.

Key Points: 
  • The sale price of the Real Property is $16.1 million.
  • Concurrent with the sale of the Real Property, the Company and the Bank, as co-tenants, and the purchaser will enter into a seventeen-year lease agreement whereby the Company and the Bank will lease back the Real Property at an initial base annual rent of approximately $926,100, subject to annual rent increases of 1.75%.
  • PDL Community Bancorp is the financial holding company for Ponce Bank and Mortgage World Bankers, Inc. Ponce Bank is a federally chartered stock savings association.
  • Ponce Bank is designated a Minority Depository Institution, a Community Development Financial Institution, and a certified Small Business Administration lender.